National Guard Health Affairs   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Riyadh Saudi Arabia (1983)

Organization Overview

First Clinical Trial
2008
NCT00636883
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ministry of National Guard-Health Affairs (MNGHA) | National Guard Health Affairs

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 4)

Coronavirus Infections (Phase 1)

Genital Neoplasms, Female (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Lung Neoplasms (Phase 4)

Pancreatic Neoplasms (Phase 2)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 10